<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011383</url>
  </required_header>
  <id_info>
    <org_study_id>SPLP-003-20F</org_study_id>
    <nct_id>NCT05011383</nct_id>
  </id_info>
  <brief_title>High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers</brief_title>
  <acronym>VA-BAT</acronym>
  <official_title>High-dose Testosterone in Men With Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether the presence of DNA repair deficiency in the form of&#xD;
      alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to&#xD;
      the use of intermittent high dose testosterone. This therapy may result in responses in&#xD;
      tumors which are genetically unstable because of DNA repair deficiency and this is a&#xD;
      prospective study to test that hypothesis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an unblinded, three cohort phase II study evaluating the efficacy of high dose&#xD;
      testosterone (BAT) for patients with mCRPC and inactivating mutations in ATM, CDK12 or CHEK2.&#xD;
      Patients will receive BAT until disease progression or intolerance, whichever occurs first.&#xD;
      Throughout the study, safety and tolerability will be assessed by frequent recording of&#xD;
      adverse events, vital signs and safety laboratory assessments. Progression will be evaluated&#xD;
      with bone scan, CT of the abdomen/pelvis and PSA as per PCWG3 criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3 cohort phase II study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response</measure>
    <time_frame>12 weeks</time_frame>
    <description>PSA response as measured by a 50% decline from baseline maintained for 12 weeks</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ATM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with castration resistant prostate cancer which contains ATM alterations are treated with high dose testosterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDK12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with castration resistant prostate cancer which contains CDK12 alterations are treated with high dose testosterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHEK2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with castration resistant prostate cancer which contains CHEK2 alterations are treated with high dose testosterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose testosterone</intervention_name>
    <description>High dose testosterone is administered subcutaneously once monthly until progression or toxicity</description>
    <arm_group_label>ATM</arm_group_label>
    <arm_group_label>CDK12</arm_group_label>
    <arm_group_label>CHEK2</arm_group_label>
    <other_name>Bipolar androgen therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form (ICF) providing agreement to adhere to the dosing&#xD;
             schedule, report for all trial visits and authorization, use and release of health and&#xD;
             research trial information&#xD;
&#xD;
          -  Male age &gt; 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone&#xD;
             (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy&#xD;
             must be maintained on effective GnRH analogue/antagonist therapy&#xD;
&#xD;
          -  Castration resistant prostate cancer as defined by serum testosterone &lt; 50 ng/ml and&#xD;
             one of the following:&#xD;
&#xD;
               -  PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions&#xD;
                  at least 1 week apart.&#xD;
&#xD;
               -  Evaluable disease progression by modified RECIST 1.1 (Response Evaluation&#xD;
                  Criteria in Solid Tumors)&#xD;
&#xD;
               -  Progression of metastatic bone disease on bone scan with &gt; 2 new lesions&#xD;
&#xD;
          -  Presence of metastatic disease on bone or CT scan&#xD;
&#xD;
          -  Patients must have progressed on 1 next-generation AR-signaling inhibitor (e.g.&#xD;
             abiraterone, enzalutamide, apalutamide, darolutamide, etc.).&#xD;
&#xD;
          -  Asymptomatic or minimal cancer related symptoms&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of &lt; 2&#xD;
&#xD;
          -  Presence of inactivating mutations in ATM, CDK12 or CHEK2 as determined by a CLIA&#xD;
             level assay for DNA sequencing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving active therapy for other neoplastic disorders will not be&#xD;
             eligible.&#xD;
&#xD;
          -  Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical&#xD;
             evidence of neuroendrocrine differentiation without morphologic evidence is not&#xD;
             exclusionary)&#xD;
&#xD;
          -  Known parenchymal brain metastasis&#xD;
&#xD;
          -  Liver metastases&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis or chronic liver disease AST or ALT &gt; 2.5 x ULN&#xD;
             or total bilirubin &gt; ULN (unless Gilbert's syndrome is the etiology of&#xD;
             hyperbilirubinemia).&#xD;
&#xD;
          -  Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt;35 % at baseline&#xD;
&#xD;
          -  Patients with pain attributable to their prostate cancer and requiring the use of&#xD;
             opioids.&#xD;
&#xD;
          -  Tumor causing urinary outlet obstruction that requires catheterization for voiding.&#xD;
             Patients that require catheterization to void secondary to benign strictures or other&#xD;
             non-cancer causes will be permitted to enroll.&#xD;
&#xD;
          -  Presence of dementia, psychiatric illness, and/or social situations limiting&#xD;
             compliance with study requirements or understanding and/or giving of informed consent.&#xD;
&#xD;
          -  Any condition(s), medical or otherwise, which, in the opinion of the investigators,&#xD;
             would jeopardize either the patient or the integrity of the data obtained.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer only develops in males</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B. Montgomery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System Seattle Division, Seattle, WA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert B Montgomery, MD</last_name>
    <phone>(206) 277-6878</phone>
    <email>Robert.Montgomery@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elahe Mostaghel, MD</last_name>
    <phone>(206) 762-1010</phone>
    <email>emostagh@fhcrc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rocky Mountain Regional VA Medical Center, Aurora, CO</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Bowles, MD</last_name>
      <phone>720-723-6498</phone>
      <email>Daniel.Bowles@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herta Chao, MD</last_name>
      <phone>203-584-0902</phone>
      <email>Herta.Chao@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical and Rehab Center, Decatur, GA</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Ribeiro, MD</last_name>
      <phone>404-728-7680</phone>
      <email>Maria.Ribeiro@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center, Kansas City, MO</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Verkruyse, MD</last_name>
      <phone>817-681-7115</phone>
      <email>Linda.Verkruyse@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis VA Medical Center John Cochran Division, St. Louis, MO</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Knoche, MD</last_name>
      <phone>314-289-6305</phone>
      <email>Eric.Knoche@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center, Durham, NC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhonda Bitting, MD</last_name>
      <phone>919-286-0411</phone>
      <phone_ext>17-5441</phone_ext>
      <email>Rhonda.Bitting@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Graff, MD</last_name>
      <phone>503-220-8262</phone>
      <email>Julie.Graff@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center, Charleston, SC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Savage, MD</last_name>
      <phone>843-792-4531</phone>
      <email>Stephen.Savage@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anita Sabichi, MD</last_name>
      <phone>713-798-3750</phone>
      <email>Anita.Sabichi@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System Seattle Division, Seattle, WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert B Montgomery, MD</last_name>
      <phone>206-277-6878</phone>
      <email>Robert.Montgomery@va.gov</email>
    </contact>
    <investigator>
      <last_name>Robert B. Montgomery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

